



Brexit: Patient and medical research charities perspective

Dr Catherine Ball
BIA and MHRA conference, 5 July

Overview

- About AMRC
- Priorities for patients and medical research
- Brexit Health Alliance
- A united voice from EU and UK patient organisations




About AMRC



144 UK medical research charity members



About AMRC



AMRC charities fund nearly half of publicly funded medical research nationally



Medical research is the top cause to which the UK public donates



1 in 8 grants awarded by AMRC members were funded in collaboration with other organisations



17,000



researchers' salaries were funded by AMRC charities, including **1,700 PhD students**

About AMRC


At all stages of the research process



AMRC members fund essential research in all areas of health and disease



Priorities for patients and medical research




People

AMRC is calling for:

- A new immigration system that supports global scientific talent and expertise

- Over a quarter of academic staff in UK universities are non-UK nationals
- More than 60% of scientists within the Crick Institute originate from outside the UK



Access to medicines

AMRC is calling for:

- Continued cooperation and coordination with the EMA
 - Frictionless supply and trade of medicines
-
- Millions of patients across the EU benefit from better access to innovative therapies and a high level of product safety as a result of comprehensive EU collaboration.
 - The UK supplies 45 million packs of drugs to Europe every month; whilst 37 million packs travel in the opposite direction.




Clinical trials

AMRC is calling for:

- Maximum collaboration between the EU and UK on clinical trials
 - Secured UK access to the CTR infrastructure
-
- Commitment from Government to align with the EU Clinical Trials Regulation as closely as possible when it comes into force.
 - Focus on trials for rare and less common diseases and other special populations.

ESPAC-4



**EUROPEAN STUDY GROUP FOR PANCREATIC
CANCER – TRIAL 4.**

Combination versus single agent chemotherapy in
resectable pancreatic cancer.

ISRCTN number: 96397343

Coordonateur International : Pr John Neoptolemos

Démarrage en France (EudraCT number: 2007-004299-38)

Pays actifs : UK (59 centres) et Suède (11 centres)

Autres pays potentiels : Allemagne, Grèce, Finlande

18Fev 2011



LCTU

Liverpool Cancer Trials Unit



EU funding and collaboration

AMRC is calling for:

- A EU-UK partnership that enables innovative collaborative research for maximum patient benefit
 - Focus on research into rare and less common diseases
-
- Confirmation that the UK will continue to participate in remainder of Horizon 2020.
 - Open door for political agreement on Associated Country status for the UK in Horizon Europe?

AUTISTICA

AIMS-2-TRIALS

Autism Innovative Medicine Studies-2-Trials

Communication

Mental Health

Physical Health

Epilepsy

“ ‘My epilepsy has improved but is still not controlled. I have sleep difficulties and lack of sleep is my primary seizure trigger. I’m also very sensitive to medication. I need drugs that work for me and don’t impact my quality-of-life.’ ”

Joseph, autistic person

Brexit Health Alliance

- Brings together the NHS, medical research, industry, patients and public health organisations
- Aims to safeguard the interests of patients and the healthcare and research they rely on
- Campaigns: patient access to medical research; access to medicines and medical technologies; reciprocal healthcare; and public health



EU & UK patient organisations are united

- EU and UK patient organisations are aligned: there must be no negative impact on patients whatever the deal agreed
- Joint letter to EU and UK negotiators outlining patient priorities in March
- Met with European Commission Taskforce on Article 50 representative on Tuesday



Questions?